Last reviewed · How we verify
placebo eye drops
placebo eye drops is a Small molecule drug developed by Allergan. It is currently FDA-approved for Clinical trial control comparator, Dry eye symptoms (placebo-responsive patients). Also known as: Control.
Placebo eye drops contain no active pharmaceutical ingredient and produce therapeutic effects solely through the placebo effect.
Placebo eye drops have been used as a control group in clinical trials studying conditions such as Fuchs' Endothelial Dystrophy and Corneal Endothelial Cell Loss. Specifically, a placebo-controlled clinical trial (NCT03575130) investigated the efficacy of Ripasudil 0.4% eye drops in Fuchs Endothelial Corneal Dystrophy.
At a glance
| Generic name | placebo eye drops |
|---|---|
| Also known as | Control |
| Sponsor | Allergan |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Placebo eye drops are inert formulations used as control comparators in clinical trials or, in some marketed contexts, as vehicles for patient expectation-driven symptom relief. They work through psychological mechanisms rather than pharmacological action on ocular tissues or molecular targets. The therapeutic benefit, if any, derives from patient belief and expectation rather than direct drug-target interaction.
Approved indications
- Clinical trial control comparator
- Dry eye symptoms (placebo-responsive patients)
Common side effects
- Minimal; adverse events typically reflect underlying condition or expectation
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Lacripep for Corneal Wound Healing Study (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (PHASE4)
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) (PHASE3)
- Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo eye drops CI brief — competitive landscape report
- placebo eye drops updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about placebo eye drops
What is placebo eye drops?
How does placebo eye drops work?
What is placebo eye drops used for?
Who makes placebo eye drops?
Is placebo eye drops also known as anything else?
What development phase is placebo eye drops in?
What are the side effects of placebo eye drops?
Related
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Clinical trial control comparator
- Indication: Drugs for Dry eye symptoms (placebo-responsive patients)
- Also known as: Control
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing